Skip to main content

Table 2 Treatment exposure, described by randomized arm, as well as within the subgroup aged ≥ 75. Reported as n (%) unless otherwise stated

From: EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Regimen received Arm A, 100 mg/m2 Arm B, 125 mg/m2
All (N = 79) Pts aged 75+ (N = 33) All (N = 79) Pts aged 75+ (N = 33)
Total n of cycles 594 214 443 180
Median n cycles (range) 6 (1–28) 6 (1–19) 6 (1–22) 5 (1–11)
Dose delays
N of patients 52 (66) 19 (58) 50 (63) 18 (55)
N of cycles 127 (21) 43 (20) 100 (23) 35 (19)
Dose reductions
N of patients 57 (72) 22 (68) 63 (80) 23 (70)
N of cycles 234 (39) 78 (36) 257 (58) 101 (56)